Related Experiment Video
Updated: Jun 24, 2025
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
A versatile dilution-treatment-detection microfluidic chip platform for rapid In vitro lung cancer drug combination
Chenchen Zhang1, Kuo Tian1, Zixun Meng1
1School of Chemistry and Chemical Engineering, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, China.
Abstract:
Combination drug therapy represents an effective strategy for treating certain drug-resistant and intractable cancer cases. However, determining the optimal combination of drugs and dosages is challenging due to clonal diversity in patients' tumors and the lack of rapid drug sensitivity evaluation methods. Microfluidic technology offers promising solutions to this issue. In this study, we propose a versatile microfluidic chip platform capable of integrating all processes, including dilution, treatment, and detection, for in vitro drug sensitivity assays. This platform innovatively incorporates several modules, including automated discrete drug logarithmic concentration generation, on-chip cell perfusion culture, and parallel drug treatments of cancer cell models. Moreover, it is compatible with microplate readers or high-content imaging systems for swift detection and automated monitoring, simplifying on-chip drug evaluation. Proof of concept is demonstrated by assessing the in vitro potency of two drugs, cisplatin, and etoposide, against the lung adenocarcinoma A549 cell line, under both single-drug and combination treatment conditions. The findings reveal that, compared to conventional microplate approaches with static cultivation, this on-chip automated perfusion bioassays yield comparable IC50 values with lower variation and a 50 % reduction in drug preparation time. This versatile dilution-treatment-detection microfluidic platform offers a promising tool for rapid and precise drug assessments, facilitating in vitro drug sensitivity evaluation in personalized cancer chemotherapy.
Insights
This study introduces a microfluidic chip for rapid in vitro cancer drug sensitivity testing. The platform streamlines drug evaluation, enabling faster, more precise personalized chemotherapy by reducing drug preparation time and improving assay consistency.
Area of Science:
- Biotechnology and Biomedical Engineering
- Cancer Research
- Microfluidics
Background:
- Combination drug therapy is vital for treating drug-resistant cancers.
- Tumor heterogeneity and slow drug sensitivity assays hinder optimal treatment selection.
- Microfluidic technology presents a potential solution for rapid drug evaluation.
Purpose of the Study:
- To develop a versatile microfluidic chip for integrated in vitro drug sensitivity assays.
- To enable automated dilution, cell culture, drug treatment, and detection.
- To facilitate rapid and precise drug assessment for personalized cancer chemotherapy.
Main Methods:
- Development of a microfluidic platform with automated drug concentration generation, on-chip cell perfusion culture, and parallel drug treatments.
- Integration of modules for seamless dilution, treatment, and detection.
- Compatibility with microplate readers and high-content imaging systems for automated monitoring.
Main Results:
- Demonstrated proof of concept using cisplatin and etoposide on A549 lung adenocarcinoma cells.
- On-chip automated perfusion bioassays yielded comparable IC50 values with lower variation than static microplate methods.
- Achieved a 50% reduction in drug preparation time compared to conventional approaches.
Conclusions:
- The developed microfluidic platform offers a rapid and precise tool for in vitro drug sensitivity evaluation.
- This technology can significantly aid in optimizing personalized cancer chemotherapy.
- The integrated approach simplifies on-chip drug evaluation, addressing current limitations in cancer treatment.
